Apimeds Pharmaceuticals (APUS) Q4 2025 earnings summary

Executive summary

• Fiscal year 2025 marked a transformation with an IPO and the acquisition of MindWave Innovations, adding a digital asset segment to the biopharmaceutical business.

• The company operates two segments: biopharmaceuticals (Apitox for knee osteoarthritis) and digital asset operations (MindWaveDAO, holding BTC, USDT, and NILA Tokens).

• No revenue was generated from biopharmaceutical or digital asset operations in 2025; digital asset gains were recognized as other income.

Financial highlights

• Net loss for 2025 was $6.0 million, up from $1.4 million in 2024, driven by increased R&D and G&A expenses.

• Total operating expenses rose to $11.9 million in 2025 from $1.3 million in 2024.

• Other income of $5.9 million in 2025 was primarily from digital asset gains post-MindWave acquisition.

• Cash and equivalents at year-end 2025 were $1.6 million, with $8.0 million in restricted cash and $2.0 million in short-term investments.

• Digital assets at fair value totaled $149.9 million as of December 31, 2025.

Outlook and guidance

• The company expects continued operating losses as it advances Apitox clinical development and builds operational infrastructure.

• Significant manufacturing costs for Apitox are anticipated in 2026.

• Management plans to address liquidity needs through additional convertible note tranches, NILA Token sales, and potential equity or debt financing.